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Introduction
Ovarian cancer is the most lethal of the gynecologic 
malignancies. Despite other cancers such as 
endometrial cancer having higher rates of incidence, 
ovarian cancer mortality rates continue to be high.1 
Ongoing work is important to screen and diagnose 
epithelial ovarian cancer (EOC) earlier, but many 
trials have failed to find an appropriate modality or 
biomarker to predict which women in the general 
population will develop this disease. As a result, most 
cases (>80%) of EOC are diagnosed at an advanced 
stage when tumor has spread to the peritoneal cavity 
and upper abdominal organs.2 This substantially 
reduces the ability to cure this malignancy, given that 
five year survival rates plummet after the disease has 
escaped the pelvic cavity.
Despite these statistics, treatment options tested 
in the past five years have revolutionized the 
management of EOC and more targeted therapies 
are on the horizon (fig 1). The treatment landscape 
for ovarian cancer has also begun to experience 
innovation in biomarker development similar to those 
for lung and colon cancer. This includes identification 
of the breast cancer BRCA gene and tumors that 
exhibit homologous recombination deficiency (HRD). 
New treatments in the sphere of poly ADP-ribose 
polymerase (PARP) inhibitors,3-6 immunotherapy, 
and heated intraperitoneal chemotherapy (HIPEC)7 
have the ability to transform the treatment paradigm 
for ovarian cancer, substantially increasing survival 
for what was uniformly thought to be a fatal cancer.
This review is targeted toward gynecologic/
surgical oncologists and medical oncologists who 
are involved in the multidisciplinary approach to 
ovarian cancer. We will review the epidemiology and 
risk factors for the development of this disease, as 
well as the surgical techniques vital to its treatment. 
Adjuvant therapies in the form of chemotherapy will 
be reviewed in the primary and recurrent/refractory 
settings. The latest controversies and avenues for 
future treatments and therapies are discussed.
Sources and selection criteria
We selected references for this review to reflect 
landmark articles that have shaped diagnosis and 
management of ovarian cancer over the past 20 
years. We searched PubMed and Embase between 
2000 and 2020 and selected peer reviewed articles in 
the English language by using the following search 
terms: ovarian cancer, neoadjuvant chemotherapy, 
primary cytoreductive surgery, lymphadenectomy, 
secondary cytoreductive surgery, hyperthermic 
intraperitoneal chemotherapy, intraperitoneal 
chemotherapy, adjuvant chemotherapy, main-
tenance therapy, recurrence, platinum sensitive 
recurrence, platinum resistant recurrence, immuno-
therapy, PARP inhibitors, bevacizumab, and chimeric 
antigen receptor therapy (CAR-T). We also identified 
references from relevant review articles, as well as 
from the similar items section of PubMed and the 
National Comprehensive Cancer Network (NCCN) 
and European Society for Medical Oncology Clinical 
Practice guidelines.8 9 We screened and reviewed 
more than 200 articles in the preparation of this 
manuscript. We prioritized publications within the 
past decade but also included more historic articles 
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that were considered landmark trials that changed 
the treatment paradigm of ovarian cancer. We 
prioritized randomized controlled trials, systematic 
reviews, meta-analyses, observational studies, 
Society of Gynecologic Oncology (SGO) consensus 
statements, and systematic reviews published within 
the past 10 years. We excluded articles published in 
non-peer reviewed journals, case reports, and case 
series.
Epidemiology and risk factors
Epithelial ovarian cancer represents the most lethal 
of the gynecologic malignancies. In 2020 more than 
300 000 new cases of EOC are expected worldwide, 
with more than 190 000 deaths.1 10 The median age 
at diagnosis is 63 years, and more than 70% of cases 
of EOC are diagnosed at advanced stages with five 
year survival rates approximating 48%.2
The lifetime risk of developing EOC is 1.3%, but 
it is as high as 40-45% for women with a BRCA1 
mutation and 15-20% for BRCA2 carriers.11 Risk 
factors for EOC include increasing age, infertility, 
endometriosis, polycystic ovarian syndrome, use of 
an intrauterine device, and cigarette smoking (for 
mucinous carcinomas). An estimated 18% of cases 
of EOC are associated with a germline mutation12; 
most of these are attributable to BRCA1 and BRCA2, 
but they also include other genes in the homologous 
recombination pathway (for example, TP53, ATM, 
MRE11, RAD51, H2AX, PALB2, RPA, BPIP1, BARD1, 
and RAD52)12-14 and mismatch repair genes.15-17
The Cancer Genome Atlas Research Network 
evaluated 316 stage II through IV high grade 
serous ovarian cancer (HGSOC) specimens and 
reported that 3% of the cases showed somatic 
BRCA1/2 mutations.18 Therefore, genetic screening 
is recommended in all patients newly diagnosed as 
having EOC.
Histological subtypes
The World Health Organization classification of tubo-
ovarian tumors includes common epithelial tumors, 
sex cord stromal tumors, germ cell tumors, soft tissue 
tumors, unclassified type, and metastatic secondary 
tumors (5-6% of adnexal masses are metastases 
from breast, gastrointestinal tract, or urinary tract). 
Given that HGSOC is the most common histological 
subtype, accounting for 75% of all EOCs, we will 
focus on this specific subgroup. Table 1 describes the 
other histology subtypes, including endometrioid, 
clear cell, low grade serous, and mucinous, in more 
detail.
Fig 1 | Evaluation and management of epithelial ovarian cancer. BSO=bilateral salpingo-oophorectomy; CA-125=cancer antigen 125; CBC=complete 
blood count; CT=computed tomography; CXR=chest ragiograph; LFT=liver function test; MRI=magnetic resonance imaging; PARPi=poly ADP-ribose 
polymerase inhibitor; TAH=total abdominal hysterectomy; USO=unilateral salpingo-oophorectomy.
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Surgery for ovarian cancer
Neoadjuvant chemotherapy versus primary 
debulking
Primary cytoreductive surgery (PCS) followed by 
platinum based chemotherapy remains the standard 
treatment for patients with advanced stage EOC. 
Thus, all women with suspected stage IIIC or IV EOC 
should be evaluated by a gynecologic oncologist 
before treatment is started, to determine whether they 
are candidates for PCS.19 Neoadjuvant chemotherapy 
may be considered for patients with bulky stage III 
or IV disease whose tumors are deemed unlikely 
to be completely cytoreduced to no gross residual 
disease (R0) or for patients who are poor surgical 
candidates. Although the choice between PCS and 
neoadjuvant chemotherapy remains controversial, 
the SGO and American Society of Clinical Oncology 
(ASCO) clinical practice guidelines state that 
for those women who have a high likelihood of 
achieving a cytoreduction to less than 1 cm (ideally 
to no visible disease) with acceptable morbidity, PCS 
is recommended over neoadjuvant chemotherapy 
(evidence quality: intermediate; strength of 
recommendation: moderate).19 Theoretical advances 
in surgical cytoreduction pertain to removal of large 
and/or poorly vascularized tumors, thus eliminating 
pharmacologic sanctuaries and allowing for optimal 
killing of the cells of the better perfused small 
residual tumors that have higher growth fractions; 
host immunocompetence is enhanced by removal 
of large tumor bulk and prevention of resistance to 
chemotherapy.20 21 A primary clinical evaluation 
should include a computed tomography scan of the 
chest, abdomen, and pelvis to evaluate the extent 
of disease and the feasibility of surgical resection. 
In exceptional cases when a biopsy is not feasible, 
cytological evaluation combined with a serum cancer 
antigen 125 (CA-125) to carcinoembryonic antigen 
ratio above 25 is acceptable to confirm the primary 
diagnosis and exclude a non-gynecologic cancer.19 
Should neoadjuvant chemotherapy be deemed 
the optimal management strategy, histological 
confirmation of EOC by biopsy is preferred over 
fine needle aspiration or paracentesis, before 
administration of neoadjuvant chemotherapy.
As our population is aging, a careful assessment of 
operability based on the patient’s age, functional and 
instrumental activities of daily living, performance 
status, comorbidities, and nutritional status is critical 
for preoperative planning, as these factors have 
been shown to predict postoperative complications, 
extended hospital stay, and six month mortality in 
older patients undergoing cancer surgery.8 22-24 The 
American College of Surgeons and the American 
Geriatrics Society have provided general guidelines 
for the preoperative assessment of older patients 
undergoing surgery.25 Patients 75 years of age or 
older who have at least one comorbidity have a 30 
day postoperative mortality of greater than 10% after 
planned PCS for stage III EOC.26
A laparoscopic surgical assessment using the 
Fagotti scoring system has been studied and 
externally validated to determine the feasibility of PCS 
to no gross residual disease.27 28 Seven parameters 
are included in this scoring system—peritoneal 
carcinomatosis, diaphragmatic disease, mesenteric 
disease, omental disease, bowel infiltration, sto-
mach infiltration, and liver metastasis. Mesenteric 
retraction was the most difficult to assess (75.2%) 
by laparoscopy, although stomach infiltration had 
the poorest negative predictive value (71.6%) and 
accuracy (77.3%). A review on predictors of optimal 
cytoreduction in patients with newly diagnosed 
advanced stage EOC commented that standard use 
of the Fagotti score should be implemented across 
different centers, with a predictive index value of 
8 or greater shown to have the best prediction of 
suboptimal cytoreduction.29
Four phase III trials have evaluated whether 
neoadjuvant chemotherapy followed by interval 
cytoreductive surgery (ICS) is effective and safe 
compared with PCS followed by platinum based 
chemotherapy (table 2).31-35 Results from these trials 
have formed the basis of clinical practice guidelines 
on neoadjuvant chemotherapy for newly diagnosed, 
advanced EOC set forth by the SGO and ASCO.30 In 
each of these trials, neoadjuvant chemotherapy 
consisted of three to four cycles of carboplatin and 
paclitaxel.
Two phase III trials showed non-inferiority of 
neoadjuvant chemotherapy with ICS compared 
with PCS followed by chemotherapy. The first 
was the European Organization for Research and 
Treatment of Cancer (EORTC)-55971, a phase III 
Table 1 | Histological subtypes of epithelial ovarian cancers and their common characteristics
Characteristics
High grade serous 





Low grade serous 
carcinoma
% of cases 70 12 11 3 3
Median age at diagnosis 61 55 56 53 43
Tumor marker(s) CA-125 CA-125 CA-125 CEA; CA19-9 CA-125
Genetic risk factors BRCA1/2 HNPCC HNPCC/BRCA Not known Serous borderline tumor
Common stage at presentation Advanced Early Early Early Advanced
Response to platinum based chemotherapy Chemo-sensitive Chemo-resistant radiosensitive Chemo-sensitive Chemo-resistant Chemo-resistant
Common gene mutations P53; BRCA1/2;  
HR defects
PIK3CA; ARD1A;  
PTEN; MSI
CTNNB1; ARID1A;  
PTEN; MSI
KRAS; HER2;  
CDKN2A
BRAF; KRAS; NRAS;  
ERBB2; PIK3CA
Common immune profile P53+; WT1+;  
Pax8+; high Ki67
HNF β+; WT1-; ER- ER+; Pax8+; vimentin+  
WT1-; P53 wild-type
CK20+; Cdx2+;  
CK7+; ER-; WT1-
WT1+; Pax8+;  
P53 wild-type; low Ki67
BRCA1/2=breast cancer susceptibility gene 1/2; CA-125=cancer antigen 125; CEA=carcinoembryonic antigen; ER=estrogen receptor; HNPCC=hereditary non-polyposis colorectal cancer; 
HR=homologous recombination; MSI=microsatellite instability; PTEN=phosphatase and tensin homolog; STIC=serous tubal intraepithelial carcinoma; TP53=tumor protein p53.
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international trial of 670 women with stage IIIC/IV 
EOC randomized to neoadjuvant chemotherapy with 
ICS versus up-front PCS.34 Median overall survival 
was equivalent (29 v 30 months for neoadjuvant 
chemotherapy v PCS), but patients who received 
neoadjuvant chemotherapy had fewer surgical 
complications. In the CHORUS trial, 550 patients 
with clinical stage III-IV disease were randomized 
to PCS followed by six cycles of chemotherapy or 
neoadjuvant chemotherapy.33 In intention to treat 
analysis, median overall survival for the PCS group 
was 22.8 months compared with 24.5 months for 
those undergoing neoadjuvant chemotherapy. 
Later, a pooled analysis of individual patient data 
from the EORTC 55971 and CHORUS trials showed 
improved survival for patients with stage IV disease 
who received neoadjuvant chemotherapy followed 
by ICS: median overall survival 24.3 months in 
the neoadjuvant chemotherapy group versus 21.2 
months in the PCS group (hazard ratio 0.76, 95% 
confidence interval 0.58 to 1.00; P=0.48) and 
median progression-free survival (PFS) 10.6 versus 
9.7 months (0.77, 0.59 to 1.00; P=0.049).34
Major criticisms of the EORTC trial relate 
to selection bias for patients at high risk that 
were not inclusive of all stage III patients and 
generalizability of surgical attempt to achieve 
R0 resection.34 The largest residual tumor was 
reported to be 1 cm or smaller in 41.6% of patients 
after PCS and in 80.6% of patients after ICS. As 
expected, median overall survival rates varied 
by largest residual tumor and treatment arm 
(neoadjuvant chemotherapy versus PCS)—overall 
survival was 38 versus 45 months for R0, 27 
versus 32 months for R1 disease, and 25 versus 20 
months for R2 disease. Despite these limitations, 
an exploratory analysis of the EORTC data helped 
to better identify which subgroups of patients with 
stage III-IV EOC benefit most from neoadjuvant 
chemotherapy versus PCS.36 Those with stage IIIC 
tumors smaller than 4.5 cm benefited more from 
PCS, whereas stage IV patients with metastatic 
tumors larger than 4.5 cm benefited more from 
neoadjuvant chemotherapy.
Importance of optimal (R0) cytoreduction
Irrespective of when surgery is performed—up front 
or after neoadjuvant chemotherapy in the primary 
setting—the goal remains removal of all visible 
tumor. As with PCS, maximal effort should be made 
to remove all gross disease in the abdomen, pelvis, 
and retroperitoneum. The volume of residual disease 
remaining after cytoreductive surgery is one of the 
most powerful determinants of survival for patients 
with EOC.37-39 One meta-analysis involving 6885 
patients with stage III or IV ovarian carcinoma 
reported that with each 10% increase in maximal 
cytoreduction, a 5.5% increase in median survival 
time was seen.39
Neoadjuvant chemotherapy should be considered 
when optimal cytoreduction is unlikely or would 
be at the cost of high perioperative morbidity 
and mortality. In these cases, ICS should be 
performed after four cycles or fewer of neoadjuvant 
chemotherapy for women who have achieved a 
response to chemotherapy or have stable disease. 
Another meta-analysis of 835 patients with 
advanced stage EOC confirmed previous findings 
that increasing percentage maximal cytoreduction 
is positively associated with median cohort survival; 
however, it also showed that a 4.1 month decrease in 
survival is seen for each extra cycle of neoadjuvant 
chemotherapy, suggesting that definitive operative 
intervention should be undertaken as early in the 
treatment course as possible.40 Ultimately, timing 
of surgery has not been prospectively evaluated and 
should be determined on an individual basis.
Bevacizumab containing regimens for neoadjuvant 
chemotherapy should be used with caution 
before ICS, given the potential for compromised 
postoperative healing. If bevacizumab is used as part 
of a neoadjuvant chemotherapy regimen, it should 
be withheld from therapy for at least 28 days before 
ICS.41
General principles of surgical cytoreduction
Surgical cytoreduction should be done by an 
experienced, high volume gynecologic oncologist 
(≥10 cases/year) at a high volume hospital (≥20 cases/
Table 2 | Trials studying neoadjuvant chemotherapy versus primary cytoreductive surgery30










SCORPION31 32 Stage IIIC-IV; Fagotti score 8-12 NACT (55) v 
PCS (55)
58% v 46%; 
P=0.16
6% v 53%; P=000001 – –
CHORUS33 Stage III-IV based on imaging or clinical 
evidence of pelvic mass with extra pelvic 
disease; CA-125/CEA >25
NACT (274) v 
PCS (276)
39% v 17%; 
P=0.0001
14% v 24%; P=0.007 12 v 10.7; HR 0.91 
(95% CI 0.76 to 1.09)
24.1 v 22.6; HR 0.87 
(0.72 to 1.05)
EORTC 5597134 Biopsy proven stage IIIC-IV. In combination with 
pelvic mass, presence of metastasis of ≥2cm 
outside the pelvis, and CA-125/CEA ≥25
NACT (334) v 
PCS (336)
51% v 19% Mortality: 0.7% v 
0.6%; sepsis: 8% v 2%; 
hemorrhage: 7% v 4%
12 v 12; HR 1.01 
(0.89 to 1.15)
30 v 29; HR 0.98  
(0.84 to 1.13); P=0.01
JCOG060235 Stage III-IV based on CT, MRI, cytological tests, 
CA-125 >200 U/mL, and CEA <20 ng/mL
NACT (152) v 
PCS (149)
63% v 30% 5% v 15%; P=0.005 - 44.3 v 49.0; HR 1.05 
(0.08 to 1.33); P=0.24
CA-125=cancer antigen 125; CEA=carcinoembryonic antigen; CT=computed tomography; HR=hazard ratio; MRI=magnetic resonance imaging; NACT=neoadjuvant chemotherapy; PCS=primary 
cytoreductive surgery.
*All were designed as non-inferiority trials except for SCORPION (superiority trial).
†Primary outcome for SCORPION.
‡Primary outcome for CHORUS, EORTC55971, and JCOG0602.
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year).42 A vertical midline abdominal incision should 
be used in most patients with suspected malignant 
EOC in whom a surgical staging procedure, a PCS, or 
an ICS is planned. Interest is growing in conducting a 
multicenter surgical trial to investigate the feasibility 
and safety of using a minimally invasive ICS for 
women who have had a complete response after three 
to four cycles of neoadjuvant chemotherapy with a 
CA-125 that has normalized.43 44 Given that nearly 
75% of patients newly diagnosed as having EOC 
present with advanced disease, surgical procedures 
that may be considered for optimal cytoreduction 
include bowel resection and/or appendectomy, dia-
phragm or peritoneal stripping, splenectomy, partial 
cystectomy and/or ureteroneocystostomy, partial 
hepatectomy, partial gastrectomy, cholecystectomy, 
and/or pancreatectomy.
Cytoreductive surgery for patients at stage IV 
can be attempted, with 30% achieving optimal 
cytoreduction. A retrospective cohort study showed 
that survival depends on the location of the stage 
IV disease. Those with pleural effusion present had 
a median survival of 19 months compared with 12 
months if lung metastasis was present, 18 months 
for parenchymal liver metastasis, and 26 months for 
those with other extraperitoneal sites.40
Removal of lymph nodes for advanced stage disease 
has also been studied. Some retrospective studies 
have suggested a potential survival benefit from 
systematic pelvic and para-aortic lymphadenectomy 
in patients with macroscopically resected advanced 
EOC, although these studies are inherently flawed by 
selection bias.
A landmark randomized international trial studied 
427 patients with stage IIB, IIIC, or IV disease, all 
of whom had optimal surgery and were randomized 
intraoperatively to systematic pelvic and para-aortic 
lymphadenectomy versus resection of bulky nodes 
only.45 All patients received adjuvant platinum based 
chemotherapy. The five year progression-free interval 
was 31.2% for the lymphadenectomy group compared 
with 21.6% for the control arm, with no difference in 
the risk of death. Patients in the lymphadenectomy 
group were more likely to need blood transfusions 
and had longer surgery and more postoperative 
complications. Although highly cited, this study was 
criticized for several reasons: participating surgeons 
were not required to prove proficiency in performing 
a complete lymphadenectomy, thus contributing to 
heterogeneity of surgical quality among participating 
centers; resection of bulky nodes was permitted in 
the no lymphadenectomy arm; and more than two 
thirds of included patients had residual postoperative 
intra-abdominal disease, which makes interpreting 
the potential benefit of lymphadenectomy difficult. 
Ultimately, because of these limitations, results of 
this trial did not change practice.
Learning from these previous criticisms, the 
Lymphadenectomy in Ovarian Neoplasms (LION) 
trial emerged.46 This was a randomized controlled 
trial of 647 patients intraoperatively randomized 
to either undergo systematic pelvic and para-aortic 
lymphadenectomy or not undergo lymphadenectomy 
if macroscopic complete resection was achieved 
and the patient had normal lymph nodes both 
before and during surgery. Median overall survival, 
the primary outcome, was 69.2 months in the no 
lymphadenectomy group and 65.5 months in the 
lymphadenectomy group (hazard ratio 1.06, 0.83 
to 1.34; P=0.65). Median PFS was 25.5 months 
in both groups, and postoperative morbidity was 
higher in the lymphadenectomy group, including 
percentage of patients receiving transfusions 
(63.7% v 56%; P=0.005), incidence of infections 
treated with antibiotics (25.8% v 18.6%; P=0.03), 
repeat laparotomy (12.4% v 6.5%; P=0.01), and 
mortality within 60 days after surgery (3.1% v 
0.9%; P=0.049). Taken together, these data suggest 
that patients with advanced EOC with normal 
lymph nodes both before and during surgery who 
undergo macroscopically complete resection do 
not benefit from systematic pelvic and para-aortic 
lymphadenectomy.
Hyperthermic intraperitoneal chemotherapy after 
cytoreduction
HIPEC with cisplatin (100 mg/m2) can be considered 
at the time of interval cytoreductive surgery for 
stage III disease (see section below). A phase III 
multicenter trial recently published results showing 
that the addition of HIPEC as a single administration 
of intraperitoneal chemotherapy to ICS improved 
recurrence-free survival (RFS) by 3.5 months and 
overall survival by 11.8 months compared with 
surgery alone, without increasing perioperative 
morbidity.7 The trial included 245 patients with stage 
III EOC who had at least stable disease after three 
cycles of neoadjuvant carboplatin and paclitaxel, who 
were randomized at the time of ICS when incomplete 
or optimal site of reduction was anticipated. Median 
RFS, the primary endpoint, was 10.7 months in the 
surgery group and 14.2 months in the surgery plus 
HIPEC group. The median overall survival was 33.9 
months in the surgery group and 45.7 months in 
the surgery plus HIPEC group. The percentage of 
patients who had adverse events of grade 3 or 4 was 
similar in the two groups (25% in the surgery group 
and 27% in the surgery plus HIPEC group; P=0.76). 
Furthermore, although the overall percentage of 
bowel resections performed was similar in the two 
groups (34% for both), the HIPEC arm had a higher 
rate of colostomy/ileostomy than the surgery arm 
(21/29 (72%) v 13/30 (43%); P=0.04). This higher 
rate was attributed to surgeons’ preference, given that 
no evidence suggests that HIPEC for ovarian cancer is 
associated with higher rates of anastomotic leakage. 
This study certainly fills a gap in the literature and 
provides another option for management, but HIPEC 
has not been widely adopted and should be practiced 
at institutions that have expertise in both delivery of 
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Primary adjuvant therapy
Adjuvant therapy for early stage ovarian cancer 
patients
The decision to recommend adjuvant therapy for 
patients with early stage EOC should be individualized 
according to histology, risk factors, adequacy of 
staging, comorbidities, and likelihood of response 
to platinum based chemotherapy. Observation is 
recommended for those with optimally staged IA 
or IB, grade 1 endometrioid carcinomas and other 
histology given that five year survival rates are greater 
than 90% with surgical treatment alone.47 48 If 
adjuvant therapy is recommended, three to six cycles 
are generally recommended.49 50 A retrospective 
analysis of GOG157, which compared three versus 
six cycles of adjuvant carboplatin and paclitaxel, 
showed improved RFS with six cycles among 
patients with HGSOC. Among non-serous tumors, 
no difference was observed between three and six 
cycles. The European Organization for Research 
and Treatment of Cancer-Adjuvant Chemotherapy 
in Ovarian Neoplasm (EORTC-ACTION) and the 
International Collaborative Ovarian Neoplasm 
(ICON1) trial were set up as parallel, complementary 
randomized trials, which showed that platinum 
based adjuvant chemotherapy, compared with 
observation, improved overall survival (hazard ratio 
0.67, 0.5 to 0.9; P=0.008) and RFS (0.64, 0.5 to 0.82; 
P=0.001) among patients with surgically resected 
early stage EOC.51 A subgroup analysis, which was 
likely to be limited by numbers, of the combined 
ICON1/ACTION data within the subcategories of age, 
stage, histology, and cell differentiation provided 
no evidence that the effect of chemotherapy was 
different within any of the subgroups.
Impact of surgical staging was assessable only 
in the ACTION trial, although only about a third of 
patients were fully staged. After a median follow-
up of 5.5 years, the original ACTION trial results 
showed that the benefit of chemotherapy seemed 
to be limited to patients with non-optimal staging. 
Long term results after a median follow-up of 10.1 
years supported most conclusions from the original 
analysis, with the exception that overall survival after 
optimal surgical staging was improved, even among 
patients who received adjuvant chemotherapy 
(hazard ratio of death 1.89, 0.99 to 3.60; P=0.05).52 
A meta-analysis of all randomized clinical trials 
comparing adjuvant chemotherapy with observation 
for patients with adequately staged I-II EOC showed 
no survival benefit of adjuvant chemotherapy 
(hazard ratio 0.91, 0.51 to 1.61).53
Adjuvant therapy for advanced stage ovarian cancer 
patients
First line chemotherapy for EOC is a platinum 
agent with a taxane. GOG111, a landmark phase 
III trial, showed improved overall survival with the 
combination of cisplatin and paclitaxel compared 
with cisplatin and cyclophosphamide.54 Other 
landmark trials that answered important clinical 
questions have shown that: carboplatin is as effective 
as cisplatin and better tolerated55; weekly dose-
dense chemotherapy with carboplatin and paclitaxel 
compared with standard three weekly chemotherapy 
does not improve long term PFS56; adding a third 
drug to a doublet chemotherapy has no additional 
benefit57-59; extended cycles of chemotherapy do not 
confer survival benefit60; and, likewise, docetaxel-
carboplatin seems to provides similar PFS and 
response to paclitaxel-carboplatin at the expense of 
more grade 3-4 neutropenia (94% v 84%; difference 
11%, 95% confidence interval 7% to 14%; P<0.001) 
but improved grade 2 or higher neurotoxicity (11% v 
30%; 15% to 24%; P<0.001).61
Intravenous versus intraperitoneal chemotherapy
In women with optimally cytoreduced, ideally 
to no gross residual, disease who have not 
received neoadjuvant chemotherapy, intravenous 
chemotherapy, or a combination of intravenous 
and intraperitoneal chemotherapy is a reasonable 
option. The appeal of intravenous/intraperitoneal 
chemotherapy stems from the need to optimize 
penetration of diffusion limited drugs, such as 
cisplatin, in a disease that is largely locoregional 
and characterized by peritoneal carcinomatosis. 
Four landmark trials (table 3) have been published 
since 1996,62-65 three showing survival benefit of 
intraperitoneal over intravenous chemotherapy, 
even among both R1 and R0 groups, and with larger 
magnitude of benefit in women who completed 
all six cycles and who had a BRCA mutation.66 
However, despite the strong rationale and survival 
efficacy, intraperitoneal chemotherapy for EOC is 
inconsistently used as standard frontline treatment.67
Several barriers affect the acceptance of intra-
peritoneal chemotherapy, including catheter related 
complications and higher rates of toxicities such 
as gastrointestinal adverse events, neutropenia, 
thrombocytopenia, and neurotoxicity. Quality of life 
was worse for patients treated with intraperitoneal 
chemotherapy, although it was comparable one year 
after completion except for neuropathy.68
The most recent trial, GOG252,65 was intended 
not only to reduce the toxicities of the GOG172 
regimen64 but also to incorporate a biologic targeted 
therapy, bevacizumab, as a primary therapy and 
maintenance, similar to GOG218. It failed to show a 
PFS benefit of intraperitoneal chemotherapy (26.8 v 
28.7 months) or intraperitoneal cisplatin (26.8 v 27.8 
months) compared with intravenous chemotherapy. 
One of the major criticisms of this trial was the fact 
that bevacizumab was used across all study arms, 
perhaps limiting the effect size of intraperitoneal 
therapy but, nevertheless, allowing the control arm 
to outperform (PFS 23.8 months) historical controls 
from GOG172 (18.3 months).
Dose dense chemotherapy
Dose dense intravenous therapy has also been 
compared with conventionally dosed intravenous 
therapy (every three weeks) as a first line treatment 
strategy in EOC with mixed results. Notable trials 
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include the Japanese GOG3016 trial, which compared 
carboplatin and paclitaxel every three weeks 
with carboplatin (every three weeks) and weekly 
paclitaxel, showing a significant benefit in PFS (28 
v 17.5 months; hazard ratio 0.76, 0.62 to 0.91) 
and overall survival (median 100.5 v 62 months; 
0.79, 0.63 to 0.99) compared with conventional 
treatment.69 Although anticipated, the same survival 
benefit was not shown in the US. In GOG262, women 
with stage II-IV EOC were randomized either to 
conventionally dosed carboplatin and paclitaxel 
or to dose dense therapy (carboplatin every three 
weeks plus weekly paclitaxel). Bevacizumab was 
allowed in both arms and administered to 84% 
of the study population.70 The primary endpoint, 
PFS, was not significantly improved among women 
who received weekly paclitaxel compared with a 
regimen of treatment every three weeks. However, 
in the subgroup of patients who did not receive 
bevacizumab, weekly paclitaxel led to a PFS that was 
3.9 months longer than that observed with paclitaxel 
administered every three weeks (14.2 v 10.3 months; 
hazard ratio 0.62, 0.40 to 0.95; P=0.03).
ICON8 involved similar study arms, comparing 
carboplatin and paclitaxel every three weeks 
(control, arm 1) versus either carboplatin (AUC 5 or 
6) every three weeks and dose dense paclitaxel (80 
mg/m2 weekly) (arm 2) or weekly carboplatin (AUC 
2) plus paclitaxel (80 mg/m2) (arm 3).71 In this phase 
III trial involving 1566 women with IC-IV EOC, no 
significant PFS increase was observed with either 
weekly regimen (24.4 months control versus 24.9 
arm 2 versus 25.3 arm 3). Grade 3-4 toxicities were 
higher with the dose dense arms (42% v 62% v 53%).
Chemotherapy considerations for older patients
Although carboplatin as a single agent has been 
advocated as a less toxic option, particularly in frail 
or elderly patients, a randomized trial of patients 
aged 70 years or older with stage III/IV EOC and 
determined by geriatric assessment to be vulnerable 
showed worse survival outcomes with single 
agent carboplatin compared with carboplatin and 
paclitaxel every three weeks or weekly.72 This led to 
premature closure of the trial. GOG273 studied the 
same age group of women (≥70 years) with newly 
diagnosed stage III/IV EOC who underwent adjuvant 
chemotherapy according to the physician’s choice of 
either single agent carboplatin (AUC 5), carboplatin 
(AUC 5) plus paclitaxel (135 mg/m2) every three 
weeks, or carboplatin (AUC 5) plus weekly paclitaxel 
(60 mg/m2). Although the trial is still ongoing, 
the authors reported their primary results, which 
showed that the instrumental activities of daily living 
score could predict the completion of four cycles of 
chemotherapy.73
A modified dose dense regimen (carboplatin 
(AUC 2) plus paclitaxel (60 mg/m2) every week for 
18 weeks) studied in the MITO7 phase III trial, was 
shown to offer better tolerability than conventional 
dosing and is often considered for medically frail 
patients.74 It was associated with decreased grade 
3-4 neutropenia (42% v 50%), febrile neutropenia 
(0.5% v 3%), grade 3-4 thrombocytopenia (1% v 
7%), and grade 2 or worse neuropathy (6% v 17%).
Maintenance after primary adjuvant therapy
Paclitaxel
The role for maintenance therapy is supported by 
GOG178, a phase III trial comparing three versus 12 
months of paclitaxel 175 mg/m2 every four weeks for 
12 cycles after completion of six cycles of platinum/
paclitaxel with a clinical complete response among 
patients with stage III-IV EOC.75 This study closed 
early after 50% enrollment and an interim analysis 
that showed an improved PFS favoring 12 cycles 
(28 v 21 months; hazard ratio 2.31, 1.08 to 4.94; 
P=0.002). However, a follow-up study showed a 
PFS of 22 versus 14 months with no overall survival 
benefit.76 As expected, the only major difference with 
Table 3 | GOG trials
Study Study groups
Progression-free survival Overall survival*
Length 
(months)
Effect size  
(95% CI) P value
Length 
(months)
Effect size  
(95% CI) P value
GOG 
10462
Cisplatin 100 mg/m2 IV; cyclophosphamide 600 mg/m2  
IV; Q3 wks × 6 cycles
NR NR NR 41 HR 0.76  
(0.61 to 0.96)
0.02
Cisplatin 100 mg/m2 IP; cyclophosphamide IV;  




Cisplatin 100 mg/m2 IV; cyclophosphamide 60 mg/m2 IV; 
Q3 wks × 6 cycles
22.2 RR 0.78 (0.66 to 0.94) 0.01 52.2 RR 0.81 (0.65 to 1.00) 0.05
Carboplatin (AUC 9) IV every 4 wks × 2; D1 taxol 135 mg/m2 




D1 taxol 135 mg/m2 (24 h); D2 cisplatin 100 mg/m2 IV 18.3 RR 0.80 (0.64 to 1.00) 0.05 49.7 RR 0.75 (0.58 to 0.97) 0.03
D1 taxol 135 mg/m2 (24 h); D2 cisplatin 75 mg/m2 IV;  




Arm 1: taxol 80 mg/m2 weekly IV; carboplatin AUC 6 IV;  
bev 15 mg/kg IV; bev maintenance × 15 cycles
24.9 Arm 1 v 2: HR 0.93  
(0.80 to 1.07); arm 1 v 3: 
0.98 (0.85 to 1.13)
NR 75.5 Arm 1 v 2: HR 0.95  
(0.80 to 1.13); arm 1 v 
3: 1.05 (0.88 to 1.24)
NR 
NR
Arm 2: taxol 80 mg/m2 weekly IV; carboplatin AUC 6 IP;  
bev 15 mg/kg IV; bev maintenance × 15 cycles
27.4 78.9
Arm 3: D1 taxol 135 mg/m2 IV (24 h); D2 cisplatin 75 mg/m2 
IP; D8 taxol 60 mg/m2 IP; bev 15 mg/kg IV; bev maintenance 
× 15 cycles
26.2 72.9
bev=bevacizumab; D=day; HR=hazard ratio; IP=intraperitoneal; IV=intravenous; NR=not reported; RR=relative risk; taxol=paclitaxel; wks=weeks.
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regard to toxicity was higher incidence of treatment 
related grade 2/3 peripheral neuropathy in the 12 
cycle treatment arm (15% v 23%), although no 
information was available on how long symptoms 
persisted after discontinuation of treatment. 
Criticisms of this trial include the allowance of 
crossover and insufficient power.
GOG175 was another trial that evaluated 
maintenance paclitaxel, but in an early staged 
population IA or IB (grade 3 or clear cell), all stage 
IC, and II EOC.77 After completion of six cycles of 
carboplatin AUC6 and paclitaxel 175 mg/m2 for 
three cycles, patients were randomized to either 
observation or weekly paclitaxel for 24 weeks. No 
differences were seen in either probability of five year 
recurrence or survival.
Pazopanib, an oral, multitarget kinase inhibitor 
of vascular endothelial growth factor receptors 1, 2, 
and 3, platelet derived growth factor receptors α and 
β, and proto-oncogene receptor tyrosine kinase, has 
also been studied in this setting. The AGO-OVAR16 
trial included 940 patients with stage II-IV EOC and 
no evidence of progression after five or more cycles 
of platinum-taxane chemotherapy, randomized 
to pazopanib or placebo for up to 24 months.58 
PFS, the primary endpoint, was prolonged in the 
pazopanib arm (7.9 v 12.3 months; hazard ratio 
0.77, 0.64 to 0.91; P=0.0021). This effect held true 
regardless of BRCA status, although a more dramatic 
benefit was seen among BRCA1/2 carriers. Common 
adverse events associated with pazopanib included 
hypertension, diarrhea, nausea, headache, fatigue, 
and neutropenia.
Angiogenesis inhibition
Bevacizumab is a humanized monoclonal antibody 
directed against vascular endothelial growth factor 
(VEGF). Given its non-overlapping toxicity profile with 
systemic chemotherapy, it is generally well tolerated, 
but it does come with serious adverse effects such as 
hypertension, proteinuria, hemorrhage, thrombosis, 
and life threatening bowel perforation. It has been 
studied in combination with chemotherapy followed 
by single agent bevacizumab maintenance therapy in 
two landmark trials, ICON7 and GOG0218, in the up-
front setting among patients with advanced EOC.78 79 
Both trials showed a modest improvement in PFS 
with incorporation of concurrent and maintenance 
bevacizumab compared with surveillance only. This 
led to European Medicines Agency (EMA) approval 
of frontline bevacizumab in the European Union in 
2011, and ultimately approval by the US Food and 
Drug Administration (FDA) along with maintenance 
bevacizumab for advanced EOC on June 13, 2018.
However, neither ICON7 nor GOG218 showed a 
difference in overall survival. A predefined subgroup 
analysis of 502 patients with a poor prognosis 
in ICON7 showed an overall survival benefit 
among patients who received bevacizumab plus 
chemotherapy compared with those who received 
chemotherapy alone (restricted mean survival time 
34.5 (95% confidence interval 32.0 to 37.0) months 
with standard chemotherapy versus 39.3 (37.0 to 
41.7) months with bevacizumab; log-rank P=0.03).78 
High risk of progression was defined as stage IV 
disease, inoperable stage III disease, or suboptimally 
debulked (>1 cm) stage III disease. Although GOG218 
also enrolled patients with high risk disease, 
crossover to bevacizumab after progression may have 
contributed to the discordance between PFS benefit 
without significant improvement in overall survival. 
GOG218 was unable to validate the overall survival 
benefit seen in ICON7, even after classifying patients 
according to ICON7 high risk criteria, but it did show 
an improved PFS and overall survival specifically in 
women with ascites,80 stage IV disease, or BRCA1/2 
mutations or those non-BRCA1/2 carriers who were 
homologous recombination deficient.79
Although studies have validated the clinical role of 
VEGF inhibition, given the modest benefit in PFS to 
approximately additional four months in exchange 
for six cycles of concurrent therapy followed by 
single agent maintenance extending beyond a year, 
without objective clinical benefit on quality of life or 
overall survival, this targeted management strategy 
should be individualized. Reserving bevacizumab 
for management of recurrent disease is reasonable 
(discussed later).
Poly ADP-ribose polymerase inhibition
Other maintenance strategies after first line chemo-
therapy, beyond VEGF inhibition, include PARP 
inhibitors. The optimal agent in this setting remains 
under investigation, but targeted therapies are 
being tested in phase III clinical trials. Two PARP 
inhibitors are approved by the FDA for maintenance 
therapy after response to first line platinum. Olaparib 
received FDA approval on the basis of SOLO-1, 
a phase III randomized, double blind, placebo 
controlled, multicenter trial evaluating the efficacy 
and safety of olaparib as maintenance monotherapy 
compared with placebo, in 391 patients with newly 
diagnosed advanced BRCA mutated ovarian cancer 
following platinum based chemotherapy.3 Olaparib 
reduced the risk of disease progression or death by 
70% (hazard ratio 0.30, 0.23 to 0.41; P<0.001), and 
at 41 months’ follow-up the median PFS for patients 
treated with olaparib was not reached compared 
with 13.8 months for patients treated with placebo. 
More recently, olaparib plus bevacizumab received 
FDA approval as first line maintenance treatment 
for patients with ovarian cancer who have complete 
or partial response to first line platinum based 
chemotherapy and whose cancer is associated with 
HRD, defined by either deleterious or suspected BRCA 
mutation and/or genomic instability. This expanded 
indication for olaparib was based on the PAOLA-1 
trial (ClinicalTrials.gov identifier NCT03737643). 
This was a phase III, randomized, double blind, 
placebo controlled, multicenter trial of 806 women 
with stage III-IV high grade serous or endometrioid 
EOC who responded to first line platinum taxane 
chemotherapy plus bevacizumab. It showed a PFS 
benefit of 4.5 months among patients randomized 
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to olaparib plus bevacizumab maintenance versus 
placebo plus bevacizumab (22.1 v 16.6 months; 
hazard ratio for disease progression or death 0.59, 
0.49 to 0.72; P<0.001).81 This survival benefit also 
extended to patients with tumors showing HRD 
regardless of BRCA status.
Veliparib (VELIA trial; NCT02470585)4 and 
niraparib (PRIMA trial; NCT02655016)5 main-
tenance therapy have also been studied, both 
showing improvement in PFS relative to placebo in 
patients with newly diagnosed advanced EOC who 
respond to platinum based chemotherapy. Notable 
highlights of each trial are summarized here. VELIA 
randomized patients 1:1:1 to three treatment 
arms—chemotherapy plus placebo followed by 
placebo maintenance (control), chemotherapy 
plus veliparib followed by placebo maintenance 
(veliparib combination only arm), or chemotherapy 
plus veliparib followed by veliparib maintenance 
(veliparib throughout arm). Benefit in PFS was seen 
only in the veliparib throughout cohort compared 
with control (23.5 v 17.3 months; hazard ratio 
0.68, 0.56 to 0.83). PRIMA, on the other hand, was 
a randomized, double blind, phase III trial that 
randomized 733 women 2:1 to receive niraparib or 
placebo maintenance after response to platinum 
based chemotherapy. Among patients with HRD, 
median PFS was significantly longer in the niraparib 
group compared with placebo (21.9 v 10.4 months; 
hazard ratio for progression or death 0.43, 0.31 to 
0.59; P<0.001). This benefit also remained when the 
overall population was analyzed (13.8 v 8.2 months; 
hazard ratio 0.62, 0.50 to 0.76; P<0.001). These trials 
reinforce the importance of identifying a patient’s 
BRCA status at the time of diagnosis. Furthermore, 
the FDA approved the Myriad myChoice CDx (Myriad 
Genetic Laboratories, Inc) as a companion diagnostic 
for niraparib and olaparib.
Ongoing and future studies
Continuing to build on the successes of the 
aforementioned trials is imperative. Ongoing 
studies are exploiting shared pathways between 
PARP inhibitors, antiangiogenics, and immune 
checkpoint inhibitors. JAVELIN Ovarian PARP 100 
(NCT03642132) was a phase III, randomized, open 
label, multicenter trial investigating avelumab 
in combination with and/or as a maintenance 
treatment following carboplatin/paclitaxel chemo-
therapy in 998 previously untreated patients with 
locally advanced or metastatic EOC. At the time 
of the planned interim analysis, an independent 
data monitoring panel determined that neither of 
the two avelumab arms would show a PFS benefit 
over the control arm of chemotherapy alone. 
The trial was terminated, but the investigation to 
determine the optimal approach to using immune 
checkpoint inhibitors in ovarian cancers is certainly 
at the forefront of research. Other important research 
considerations include what the optimal control arm 
is and whether using adaptive platform trial designs 
is feasible in EOC trials, whereby a single protocol 
simultaneously evaluates multiple treatments, 
dropping arms for futility, declaring superiority of 
one arm over another, or even adding new treatment 
arms as the trial progresses.82
Surveillance
The SGO published a position statement for post-
treatment surveillance with the goal of providing 
cost effective, evidence based strategies to optimize 
oncologic outcomes.83 Patients who are in complete 
clinical remission after their initial treatment should 
receive close surveillance follow-up every three to 
four months for years 0-2, every four to six months 
for years 2-3, every six months from years 3-5, and 
then annually after five years. These visits should 
include symptom management, examination by a 
physician including a pelvic examination, and long 
term wellness care. Patients should be educated 
about the signs and symptoms of recurrence, 
particularly pelvic pain, bloating, early satiety, 
obstruction, unintentional weight loss, and fatigue. 
The NCCN also recommends that referral for genetic 
risk evaluation should be done if not previously 
performed.
If the CA-125 concentration was initially elevated, 
measurement of CA-125 or other tumor markers is 
recommended during surveillance follow-up. The 
sensitivity and specificity of CA-125 for detecting 
recurrences range from 62% to 94% and from 
91% to 100%, respectively. However, data suggest 
that treating recurrence early on the basis of 
detectable CA-125 concentrations in patients who 
are asymptomatic may not lead to an increase in 
survival and may be associated with a decreasing 
quality of life.84 Supportive of this, the EORTC 
conducted a randomized trial assessing the outcome 
of 527 patients who were treated for recurrent EOC 
based on CA-125 alone compared with clinically 
evident recurrence.85 Overall survival did not differ 
between the groups, and the authors concluded that 
routine measurement of CA-125 is not warranted for 
disease surveillance. Similarly, a post hoc analysis 
of patients with recurrent, platinum resistant EOC in 
the AURELIA trial showed that progression of disease 
was detected earlier by imaging than by CA-125, but 
this did not lead to any meaningful difference in 
overall survival.86
Thus, imaging should be obtained when recur-
rence is suspected and may include computed 
tomography scan of the chest, abdomen, and 
pelvis (sensitivity 40-93%, specificity 50-98% for 
recurrent disease).87 However, given the limitations 
of computed tomography scans to detect small 
volume disease, other imaging modalities may be 
considered, including magnetic resonance imaging 
(sensitivity 62-91%, specificity 40-100%)88 or 
positron emission tomography (sensitivity 45-100%, 
specificity 40-100%).88-90 Ultrasonography may be 
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Recurrent ovarian cancer
Platinum sensitivity
Platinum sensitivity is generally defined as an interval 
of greater than six months between the last cycle of 
platinum based chemotherapy (PBC) and the start of 
the subsequent course of platinum. Approximately 
60-70% of patients with a platinum-free interval 
(PFI) of more than 24 months will likely respond to 
re-treatment with platinum. Although the way PFI 
is defined varies—whether by serology only or by 
radiographic findings of progressive disease—studies 
have sought to test the hypothesis that prolonging 
the PFI with a non-platinum agent may improve the 
subsequent response to platinum.91-93 The OVA301 
study is an important trial to highlight differences in 
practice across the world and the practical challenges 
we face for patients with partially platinum sensitive 
recurrence with a PFI of six to 12 months. Although 
OVA301 also included platinum resistant patients, 
a post hoc analysis of 214 cases with partially 
platinum sensitive relapse (PFI of 6-12 months)94 
showed that the combination of trabectedin plus 
pegylated liposomal doxorubicin (PLD) versus PLD 
alone delayed subsequent platinum treatment by 2.5 
months and led to an improved PFS (7.4 v 5.5 months; 
hazard ratio 0.65; P=0.015) and a 41% decrease in 
the risk of death (overall survival 23 v 17.1 months; 
hazard ratio 0.59; P=0.0015).95 On the basis of these 
results, trabectedin-PLD combination was approved 
in the European Union for patients with platinum 
sensitive recurrent EOC, but the US FDA required 
additional data to support the combination. The 
final overall survival analysis of 672 women (522 
deaths) did not meet the protocol defined criterion 
for statistical significance (95% confidence interval 
0.72 to 1.02; P=0.0835).96 The study was originally 
powered to detect a 33% increase in overall survival. 
Of note, an unexpected imbalance of PFI was seen, 
favoring the PLD arm. An ad hoc prognostic factor 
adjusted analysis of overall survival suggested that a 
benefit might have been seen in patients treated with 
trebectedin-PLD if the PFI were balanced between 
study arms. INOVATYON, a prospective phase III trial 
comparing trabectedin-PLD followed by platinum 
versus PBC (NCT01379989), has completed accrual, 
and we are currently awaiting trial results.
Results from MITO8 are consistent with the final 
analysis of OVA301 and call into question whether 
a survival benefit is gained by extending the PFI 
among patients with partially platinum sensitive 
EOC that recurs after six to 12 months.97 This was 
an international, multicenter, open label phase 
III randomized controlled trial in 215 patients, 
comparing non-platinum based chemotherapy 
(NPBC) followed by PBC at subsequent relapse 
with the standard sequence of PBC followed by 
NPBC.97 NPBC was PLD in more than 85% of cases. 
PFI was prolonged in the experimental arm (7.8 v 
0.01 months), but no overall survival benefit was 
seen, and quality of life was significantly worse 
in the experimental arm. The meaning of PFI only 
becomes more convoluted when we consider the 
current era of maintenance therapies after first 
line treatment, including PARP inhibitors and 
bevacizumab.
Surgery for recurrent ovarian cancer
Recent data on the role of secondary cytoreductive 
surgery from prospective randomized trials have filled 
a gap in the literature in an era when maintenance 
therapy with bevacizumab, PARP inhibitors, or both is 
quickly becoming a mainstream strategy with proven 
PFS benefit among patients with platinum sensitive, 
recurrent disease. GOG213 was an open label, 
phase III, multicenter, international, randomized 
clinical trial of 485 patients with platinum sensitive, 
recurrent EOC who had received one previous therapy 
and whose disease the investigator determined to be 
resectable.98 Women were randomized 1:1 either to 
secondary surgical cytoreductive surgery followed 
by adjuvant PBC or to receive PBC alone. Choice of 
adjuvant chemotherapy (paclitaxel-carboplatin or 
gemcitabine-carboplatin) and bevacizumab was left 
to the treating physician. With regard to the primary 
endpoint, the study showed that secondary surgical 
cytoreduction followed by chemotherapy did not 
result in longer overall survival than chemotherapy 
alone (median overall survival 50.6 v 64.7 months; 
hazard ratio for death 1.29, 0.97 to 1.72; P=0.08). 
This effect was not altered after adjustment for PFI 
and chemotherapy choice. Median PFS was 18.9 
months and 16.2 months, and the hazard ratio for 
disease progression or death was 0.82 (0.66 to 1.01). 
As highlighted in the authors’ discussion, dilution 
of an independent surgical effect could be due to 
selection bias of patients who were considered to 
have “substantial platinum-sensitivity” with a 
median PFI of 20.4 months and relatively limited 
tumor volume, with more than half having two or 
fewer sites of recurrence.
Two phase III randomized clinical trials 
are evaluating this clinical question: an 
Arbeitsgemeinschaft Gynaekologische Onkologie 
(AGO) trial entitled Descriptive Evaluation of 
Preoperative Selection Criteria for Operability in 
Recurrent EOC (DESKTOP) III (NCT01166737) and 
Surgery or Chemotherapy in Recurrent Ovarian 
Cancer (SOC 1; NCT01611766). The Netherlands 
SOCceR trial (NTR3337) recently closed to accrual, 
and we anxiously await the results. Presented as an 
abstract at the ASCO meeting in 2017, preliminary 
results from DESKTOP III suggested a PFS benefit of 
5.6 months (19.6 v 14.0 months; P<0.001) and longer 
time to the start of subsequent chemotherapy (21.0 v 
13.9 months; P<0.001) among women with platinum 
sensitive recurrent EOC who underwent secondary 
cytoreduction versus a platinum containing second 
line therapy. The primary endpoint of overall survival 
is still not mature.99 The most notable differences 
between GOG213 and DESKTOP III lay in the patient 
selection criteria and adjuvant therapy, particularly 
the rate of maintenance bevacizumab (84% and 
20%, respectively). Taken together, maturity of 
data from DESKTOP III and the other two trials will 
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hopefully bring clarity to the value of surgery in this 
patient population.
Platinum sensitive recurrence
Platinum based chemotherapy for recurrent disease
Individualization of management strategies should 
consider previous tolerance of chemotherapy, 
residual symptoms, and current performance status. 
We recognize that not all patients are candidates for 
platinum doublets, but the modest PFS benefit of 
combination therapy compared with single agent 
platinum should be factored into the shared decision 
making. Table 4 lists landmark trials that have helped 
to shape the landscape of chemotherapy for patients 
with recurrent, platinum sensitive EOC.100-105 
ICON4/OVAR2.2 was the first phase III randomized 
controlled trial comparing platinum monotherapy 
with platinum and paclitaxel therapy in women with 
relapsed EOC.100 The benefit in overall survival (29 
v 24 months; hazard ratio 0.82; P=0.02) and PFS 
(12 v 9 months; 0.76; P<0.001) with combination 
therapy set the stage for future trials that often use 
the platinum-taxane combination as a reference 
group. This finding was also confirmed in a meta-
analysis, which showed that combination PBC was 
associated with improved overall survival (hazard 
ratio 0.80; P=0.05) and PFS (0.68; P<0.001).106 
Separate subgroups analysis defined by previous 
paclitaxel exposure, PFI (6-12 v 12 months), or 
number of previous lines of chemotherapy did not 
show a difference in the relative effect of combination 
chemotherapy on either PFS or overall survival.
Subsequent trials aimed to study different platinum 
combinations that would confer survival benefit 
while minimizing toxicities. A phase III randomized 
controlled trial showed that the combination of 
gemcitabine plus carboplatin versus carboplatin 
improved PFS by 2.8 months (8.6 v 5.8 months; 
hazard ratio 0.72; P=0.003), with no difference in 
overall survival and increased myelosuppression 
(70% had grade 3-4 neutropenia and 35% had 
grade 3-4 thrombocytopenia).101 Similarly, the non-
inferiority randomized controlled trial CALYPSO 
showed that carboplatin and PLD compared with 
carboplatin and paclitaxel improved median PFS 
(11.3 v 9.4 months; hazard ratio 0.82; P=0.005) 
without an overall survival benefit (hazard ratio 
0.99; P=0.87) at the expense of increased hand-foot 
syndrome (12.0% v 2.2%), nausea (35.2% v 24.2%), 
and mucositis (13.9% v 7%).102 107
Bevacizumab
Bevacizumab has been studied extensively in patients 
with platinum sensitive tumors, in combination 
with chemotherapy and followed by single agent 
maintenance therapy—OCEANS, GOG213, and AGO-
OVAR2.21 (table 4). The prolongation in PFS by four 
months in this setting is what led to approval by the 
US FDA and the EMA for the treatment of platinum 
sensitive, recurrent EOC.
One of the more practical challenges that oncologists 
face is whether to re-treat with bevacizumab in 
a patient with platinum sensitive EOC who has 
already received bevacizumab as part of the first line 
treatment of her disease. Presented in abstract form 
at ASCO’s 2018 annual meeting, MITO16B-MaNGO 
OV2B-ENGOT OV17 (NCT01802749) considered this 
question and showed a prolongation of PFS by three 
months (11.8 v 8.8 months; hazard ratio 0.51, 0.41 
to 0.64; P<0.001) in patients with platinum sensitive, 
recurrent EOC re-treated with bevacizumab plus 
concomitant second line chemotherapy (carboplatin-
paclitaxel, carboplatin-gemcitabine, or carboplatin-
PLD) followed by bevacizumab maintenance 
compared with platinum doublet chemotherapy 
alone.108 Median overall survival was 27.1 months 
and 26.7 months without and with bevacizumab 
(hazard ratio 1.00, 0.73 to 1.39; P=0.98), with no 
unexpected toxicity.
PARP inhibitors
Both the FDA and EMA have approved three different 
PARP inhibitors to expand the armamentarium 
of targeted therapeutics for patients with EOC 
(table 5). PARP inhibitors were first approved for 
use as single agents in patients with recurrent 
EOC with deleterious germline or somatic BRCA 
mutations who had not responded to previous lines 




Progression-free survival Overall survival
Length 
(months)
Hazard ratio  
(95% CI) P value
Length 
(months) Hazard ratio (95% CI) P value
ICON4100 OS Carbo 10 0.76 (0.66 to 0.89) 0.0004 24 0.82 (0.69 to 0.97) 0.02
Carbo/taxol 13 29
AGO101 PFS Carbo 5.8 0.72 (0.58 to 0.90) 0.003 17.3 0.96 (0.75 to 1.23) 0.73
Carbo/gem 8.6 18.0
CALYPSO102 PFS Carbo/taxol 9.4 0.82 (0.72 to 0.94) 0.005 30.7 0.99 (0.85 to 1.16) 0.94
Carbo/PLD 11.3 33.0
OCEANS103 PFS Carbo/gem/placebo 8.4 0.48 (0.39 to 0.61) <0.0001 32.9 0.95 (0.77 to 1.17) 0.65
Carbo/gem/bev 12.4 33.6
GOG 213104* PFS Carbo/taxol 10.4 0.63 (0.53 to 0.74) <0.001 37.3 0.83 (0.68 to 1.01) 0.06
Carbo/taxol/bev + bev maintenance 13.8 42.2
AGO-OVA 2.21/
ENGOT105
PFS Carbo/gem/bev + bev maintenance 11.7 0.80 (0.68 to 0.96) 0.013 NR NR NR
Carbo/PLD/bev + bev maintenance 13.3 NR
bev=bevacizumab; Carbo=carboplatin; gem=gemcitabine; NR=not reported; PLD=pegylated liposomal doxorubicin.
*OS based on audited treatment-free interval stratification data: hazard ratio 0.823 (0.68 to 0.996); P=0.0447.
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of chemotherapy. However, the substantial PFS 
advantage that is sustained with maintenance PARP 
inhibition after response to PBC has made them the 
preferred strategy in this setting, especially among 
patients who harbor a germline or somatic BRCA 
mutation. This benefit has also extended to those 
who have HRD and, although to a lesser degree, to 
patients with BRCA wild-type and even to patients 
who have residual disease after responding to PBC. 
However, a benefit in overall survival has not yet 
been shown owing to the need for longer follow-up.
A practical dilemma that we will be faced with is 
the management strategy to treat patients who have 
recurrent platinum sensitive ovarian cancer and 
have been previously treated with frontline PARP 
maintenance. In this situation, enrolling the patient 
in a clinical trial would be the first recommendation, 
but inevitability oncologists will be faced with the 
decision between maintenance bevacizumab and re-
challenge with PARP inhibitor. For the latter, whether 
the PARP inhibitor should be the same as the one used 
previously or a different brand remains unclear. An 
abstract presented at the 2019 SGO annual meeting 
described a retrospective, multi-institutional study 
of 22 patients with EOC that investigated previous 
exposure to PARP inhibitor.109 Treatment with a 
second PARP inhibitor most often involved niraparib 
(10; 45%), olaparib (6; 27%), or rucaparib (6; 27%), 
with none using veliparib, and the most common 
reason for discontinuing treatment was progression 
(13; 59%) followed by toxicity (6; 27%). Until more 
research is forthcoming, selection of maintenance 
therapy should be based on considerations of current 
and potential toxicities related to each therapy as 
well as response to previous therapies. Mechanisms 
of resistance to PARP inhibitors and prediction of 
resistance are important areas of ongoing research.
Four randomized phase III trials have reported 
their outcomes on PARP inhibitor maintenance for 
patients with platinum sensitive, recurrent EOC 
(table 6), all supporting the clinical benefit of using 
PARP inhibitors as maintenance therapy for those 
who are responding to PBC.6 110-112 NOVA and ARIEL3 
extended their inclusion criteria to encompass 
patients regardless of their BRCA status and 
investigated the impact of other biomarkers, such as 
loss of heterozygosity/homologous recombination 
status, to predict response to treatment.111 112 Other 
notable discrepancies related to the inclusion criteria 
are BRCA mutation status and amount of residual 
disease allowed. Furthermore, even though PFS was 
consistently chosen as the primary outcome, the 
method of assessment differed between studies—all 
but STUDY19 used investigator assessed PFS only.6
Future directions for PARP inhibitors
The current landscape of trials for platinum sensitive 
recurrent EOC is exciting and quickly expanding, 
with trials that are investing not only the role of 
PARP inhibitors in combination with antiangiogenic 
agents or immune checkpoint inhibition (discussed 
below) but also the concept of PARP inhibitor 
maintenance retreatment. Combining molecular 
targeted therapies for women with platinum 
sensitive recurrent EOC, particularly for those who 
lack a known BRCA mutation, is another important 
area of research. A randomized, phase II trial of 
90 women with measurable, platinum sensitive 
recurrent EOC showed that the combination of 
olaparib with cediranib versus olaparib alone 
significantly improved median overall response 
rate (ORR) by 32% and median PFS by 8.7 months 
(17.7 v 9.0 months; hazard ratio 0.42, 0.23 to 0.76; 
P=0.005).113 As expected, grade 3-4 adverse events 
were more common with the combination therapy, 
including fatigue (27% v 11%), diarrhea (23% v 
0%), and hypertension (39% v 0%). Subset analysis 
showed significant benefit on PFS in gBRCA wild-
type/unknown patients receiving olaparib-cediranib 
compared with olaparib alone (16.5 v 5.7 months; 
P=0.008). More recently, a press release from 
AstraZeneca and Merck reported that the addition of 
cediranib to olaparib did not result in improved PFS 
in comparison with PBC in patients with platinum 
sensitive recurrent EOC, which was the primary 
endpoint of the phase III NRG-GY0004 trial.114 
Phase II AVANOVA (NCT02354131) will randomize 
patients with platinum sensitive recurrent EOC to 
either niraparib or niraparib plus bevacizumab.
Other current research initiatives are studying the 
role of PARP inhibitors after exposure to initial PARP 
inhibitors used upfront as first line maintenance 
therapy. The MOLTO (Multi-maintenance Olaparib 
After Disease Recurrence in Participants With 
Table 5 | Poly ADP-ribose polymerase (PARP) inhibitors for patients with epithelial ovarian cancer (EOC)
Drug Time of approval Agency Indications BRCA status Clinical setting Dosing
Olaparib December 2018 FDA Advanced EOC, post CR/PR to platinum based chemotherapy g/sBRCA First line maintenance 300 mg BID
August 2017 Advanced EOC gBRCA Monotherapy, fourth line
Platinum sensitive recurrent OC, post CR/PR - Maintenance
February 2018 EMA Platinum sensitive recurrent HGOC, post CR/PR - Maintenance
Rucaparib December 2016 FDA Advanced OC g/sBRCA Monotherapy, third line 600 mg BID
April 2018 Platinum sensitive recurrent OC, post CR/PR - Maintenance
May 2018 EMA Platinum sensitive recurrent or progressive HGOC g/sBRCA Monotherapy, third line
Jan 2019 Platinum sensitive recurrent OC, post CR/PR - Maintenance
Niraparib March 2017 FDA Platinum sensitive recurrent OC, post CR/PR - Maintenance 300 mg QD
September 2017 EMA Platinum sensitive recurrent HGSOC, post CR/PR - Maintenance
BID=twice daily; BRCA=breast cancer susceptibility gene; CR/PR=complete response or partial response; EMA=European Medicine Agency; FDA=Food and Drug Administration; g/
sBRCA=germline and/or somatic BRCA1/2 mutation; HGOC=high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer; HGSOC=high grade serous epithelial ovarian, fallopian 
tube, or primary peritoneal cancer; OC=epithelial ovarian, fallopian tube, or primary peritoneal cancer; QD=once daily.
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Platinum-Sensitive BRCA mutated High Grade Serous 
Ovarian Cancer) study (NCT02855697) is a phase I 
study that includes BRCA1/2 patients, and OREO 
(Olaparib Maintenance Retreatment in Patients 
with Epithelial Ovarian Cancer) is a phase III study 
(NCT03106987) involving patients with and without 
BRCA mutations.
Platinum resistant recurrence
Platinum resistant EOC is defined as recurrence of 
disease within six months of completion of surgery 
and adjuvant chemotherapy. Platinum resistance 
generally portends a very poor prognosis, with 
overall survival rates from the time of diagnosis of 
resistant disease of only 12-14 months. Discussions 
about goals of care and quality of life, essential to 
any cancer discussion, are critical at this junction 
as this class of ovarian cancer is almost uniformly 
incurable. Surgery is almost always avoided in this 
patient population, although some exceptions may 
exist.
Monotherapy strategies
Monotherapy for platinum resistant disease achieves 
minimal responses of the order of 10-20%. Single 
agent therapy includes weekly paclitaxel with a 
response rate of up to a 21% in a phase II clinical 
trial, with minimal grade 3-4 side effects.115 Another 
phase III trial compared the use of topotecan with 
PLD every 28 days and found similar response rates 
and overall survival (up to 13 months) with less 
toxicity in the PLD arm.116 117
Angiogenesis therapy
In an attempt to enhance these response rates, 
the addition of bevacizumab to these three agents 
(topotecan, taxol, and PLD) was examined in a 
large phase III trial, AURELIA. Nearly 400 patients 
were randomized to single agent therapy with the 
aforementioned drugs or doublet therapy with the 
addition of bevacizumab. Inclusion criteria were 
very specific to exclude previous anti-angiogenesis 
treatment, bowel obstruction, or more than two 
previous lines of treatment. Outcomes showed 
improved an ORR of 31%, improved PFS (6.7 
months), and generally good tolerability with the 
addition of bevacizumab. A subset analysis showed 
that weekly paclitaxel with bevacizumab (ORR 
53%) may offer the best benefit compared with 
the other doublet regimens, although it requires 
weekly infusions. No overall survival advantage was 
seen with the addition of bevacizumab. Another 
regimen to consider is cisplatin/gemcitabine plus 
bevacizumab, which was examined in a phase II 
Table 6 | Poly ADP-ribose polymerase (PARP) inhibitor maintenance for patients with platinum sensitive, recurrent ovarian cancer
Olaparib Rucaparib Niraparib
STUDY196 SOLO2110 ARIEL3111 NOVA112
Design
No of patients 265 295 564 553
Population Platinum sensitive recurrent 
HGSOC; PR/CR after ≥2 previous 
lines of PBC
Platinum sensitive recurrent HGS 
or endometrioid OC; PR/CR after ≥2 
previous lines of PBC
Platinum sensitive recurrent HGS or 
endometrioid OC; PR/CR after ≥2 previous 
lines of PBC ≥2 previous lines of PBC
Platinum sensitive HGSOC; PR/
CR after ≥2 previous lines of PBC
Eligible BRCA status gBRCA; sBRCA; BRCAwt gBRCA; sBRCA gBRCA; sBRCA; BRCAwt gBRCA; sBRCA; BRCAwt
HRD assessment - - FoundationFocus CDxBRCA LOH myChoice HRD
Randomization 1:1 2:1 2:1 2:1
Intervention Olaparib 400 mg BID (capsules) 
v placebo
Olaparib 300 mg BID  
(tablets) v placebo
Rucaparib 600 mg BID v placebo Niraparib 300 mg daily v 
placebo
Primary endpoint Investigator assessed PFS Investigator assessed PFS Investigator assessed PFS Investigator assessed PFS  
and PFS by BICR
QOL assessment FACT-O; FOSI FACT-O; EQ-5D-5L NFOSI-18; DRS-P FOSI; EQ-5D-5L
Results
PFS g/sBRCAm - 19.1 v 5.5 months; HR 0.30  
(95% CI 0.22 to 0.41); P<0.001
16.6 v.5.4 months; HR 0.23  
(0.16 to 0.34); P<0.001
21.0 v. 5.5 months; HR 0.27 
(0.17 to 0.41); P<0.001
PFS gBRCAwt - 7.4 v 5.5 months; HR 0.54  
(0.34 to 0.85); P=0.0075
- 9.3 v 3.9 months; 0.45  
(0.34 to 0.61); <0.001
PFS HRD or LOH high - NA 9.7 v 5.4 months*; HR 0.44  
(0.29 to 0.66); P<0.001
12.9 v 3.8 months; HR 0.38 
(0.24 to 0.59);P<0.001
PFS HRP or LOH low - NA 6.7 v 5.4 months*; HR 0.58  
(0.40 to 0.85); P=0.0049
6.9 v 3.8 months; HR 0.58  
(0.36 to 0.92); P=0.02
Toxicities (%)
Dose reduction - 25 55 66
Drug discontinued - 11 13 14
Any grade >3 AE* - 36 36 36
Anemia - 25 19 25
Neutropenia - 20 7 20
Thrombocytopenia - 34 5 34
Nausea - 3 4 3
Fatigue - 8 7 8
AE=adverse event; BICR=blinded independent central review; BID=twice daily; BRCA=breast cancer susceptibility gene; BRCAwt=BRCA wild-type; g/sBRCAm=germline and/or somatic BRCA1/2 
mutation; DRS-P=disease related symptoms-physical; FACT-O=Functional Assessment of Cancer Therapy-Ovarian; FOSI=FACT/NCCN Ovarian Symptom Index; HR=hazard ratio; HRD=homologous 
recombination deficient/deficiency; HGS=high grade serious; HRP=homologous recombination proficient LOH=loss of heterozygosity; NFOSI-18=NCCN/FACT Ovarian Symptom Index (subset of 
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clinical trial of both platinum resistant and platinum 
sensitive patients (n=35).118 Interestingly, although 
numbers were small, a 78% complete and partial 
response rate was seen although 29% experienced 
grade 3-4 neutropenia. Given the incurable nature 
of this disease, management options for most 
patients are often based on ongoing toxicities and 
the potential impact of future treatments on quality 
of life. Incorporation of bevacizumab is a reasonable 
option on the basis of the AURELIA trial, knowing 
that the ideal candidate is one who has received 
fewer than two previous regimens, has no previous 
exposure to bevacizumab, and has no history of a 
bowel obstruction in the previous six months (or no 
evidence of malignant bowel involvement).
The use of immunotherapy (discussed in detail 
below) and PARP therapy presents a potential new 
frontier in the treatment of platinum resistant EOC. 
The results of the phase II TOPACIO/KEYNOTE-162 
trial showed that 300 mg of daily niraparib orally 
with 200 mg of intravenous pembrolizumab every 21 
days had a 13% and 47% partial and stable response 
rate, respectively.119 The disease control rate of 65% 
was impressive in this cohort of platinum resistant 
patients. The QUADRA study evaluated the efficacy 
of single agent niraparib at 300 mg daily in a heavily 
pretreated group (three or more previous lines of 
chemotherapy) of patients with recurrent EOC.120 
A total of 463 patients were enrolled, of whom 
151 (33%) had platinum resistant disease and 161 
(35%) were refractory to platinum. ORR was as high 
as 28%, with a low complication rate globally. Given 
that quality of life is of paramount importance, the 
use of an oral agent to obtain treatment response is 
important in this group.
Another notable trial for this specific population 
is the randomized, open label, phase III JAVELIN 
Ovarian 200 trial presented at the 2019 SGO Annual 
Meeting on Women’s Cancer. Avelumab alone or in 
combination with pegylated liposomal doxorubicin 
did not meet its primary objectives of significantly 
improving PFS or overall survival among patients 
with platinum resistant or refractory EOC. However, 
the planned subgroup analysis suggested that 
patients with PD-L1 positive tumors (58% of 
patients) had improved PFS (3.7 v 1.9 months) and 
improved overall survival (18.4 v 13.8 months) for 
avelumab-PLD versus PLD.
Emerging and novel therapies
Immunotherapy
Immunotherapy presents a potentially novel 
frontier in the treatment of recurrent EOC. Immune 
checkpoints are regulators of the immune system, 
intended to maintain self-tolerance and prevent 
autoimmunity. However, some cancers can protect 
themselves from immune attack by stimulating 
immune checkpoint targets. Studies have shown 
the efficacy of immune based therapies with 
improved survival in a host of cancers including 
metastatic melanoma, renal cell carcinoma, and 
lung cancer.121-123 In particular, the association of 
intratumoral tumor infiltrating lymphocytes and 
improved clinical outcomes for EOC patients suggests 
that this tumor type is potentially immunoreactive, 
but preliminary trials have shown mixed results with 
regard to the efficacy of these modalities.
Given that this is an evolving area of active 
research, we highlight here only a few studies 
involving the combination of checkpoint inhibitors 
with PARP inhibitors, bevacizumab, or both. The 
basis of studying such combinations stems from 
mouse models that have shown that PARP inhibitors 
can activate interferon signaling and synergize 
with programmed cell death 1 (PD-1) or cytotoxic 
T lymphocyte associated protein-4 (CTLA-4) 
blockade.124 Translating this to early phase clinical 
trials, the MEDIOLA study was presented as a late 
breaking abstract at SGO 2018. It was an open label, 
phase II basket study of durvalumab (anti-PD-L1) in 
combination with olaparib, studied in 32 patients 
with platinum sensitive recurrent BRCA mutated 
tumors and resulted in an ORR of 72%, including a 
complete response rate of 19%.125 Among patients 
with BRCA wild-type tumors, the combination 
resulted in an ORR of 17% and a disease control rate 
of 83% at six months. Overall, it was well tolerated, 
although the most frequent grade 3 or higher adverse 
events were anemia (12%) and increased lipase (9%); 
the most common immune related adverse events (all 
grades) were hypothyroidism (15%) and rash (12%). 
As mentioned above, results from the phase I/II 
TOPACIO/KEYNOTE-162 trial confirmed tolerability 
and antitumor activity in recurrent EOC patients with 
the combination of the PARP inhibitor niraparib with 
an anti-PD-1 antibody, pembrolizumab.119
A recent phase II trial of 38 patients has shown the 
efficacy of combining a PD-1 inhibitor, nivolumab, 
with bevacizumab and showed a 40% ORR in patients 
with platinum sensitive tumors and mean PFS of 12.1 
months.126 Of note, a phase II study of nivolumab 
monotherapy found a 15% ORR in patients with 
platinum resistant disease, with a mean PFS of 3.5 
months and overall survival of 20 months.127 Other 
combination immunotherapies such as nivolumab 
with the CTLA–4 targeted therapy ipilimumab have 
shown up to 31% ORR and a hazard ratio of 0.59 for PFS 
in patients with platinum sensitive, recurrent EOC.128
Folate receptor antibody drug conjugates
Folate receptor antibody drug conjugates such as 
mirvetuxumab soravtansine are another potential 
avenue to therapy in patients with platinum resistant, 
recurrent ovarian cancer. This was explored in a phase 
IB trial of 66 patients treated with mirvetuxumab and 
bevacizumab.129 The objective response rate of 39% 
and mean PFS of 6.8 months showed substantial 
promise for the use of this doublet combination in a 
heavily pretreated recurrent population. Ocular side 
effects such as blurred vision as well as keratopathy 
must be managed by proactive mitigation strategies 
(for example, lubricating and steroid eye drops) 
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Mismatch repair and microsatellite instability in 
ovarian cancers
Testing for microsatellite instability and defects 
in mismatch repair is increasingly being used to 
identify point mutations that may offer targeted 
therapies in ovarian cancer. Defects in mismatch 
repair substantially increase the risk of developing 
ovarian cancer as part of hereditary cancer 
syndromes such as hereditary non-polyposis 
colorectal cancer. Identification of these defects 
in ovarian cancer patients is important both for 
genetic testing of family members and for the use 
of novel therapies. New data suggest that mismatch 
repair deficient and microsatellite instability-H 
ovarian cancer tumors may predict responsiveness 
to anti-PDL-1 immunotherapy agents such as 
pembrolizumab.130 The KEYNOTE-028 trial showed 
that in a subset of PDL-1 positive patients with 
EOC, pembrolizumab conferred durable antitumor 
activity with manageable safety and toxicity.131 Use 
of molecular markers such as MSI-H and PDL-1 is 
thus important in the armamentarium of targeted 
therapies in ovarian cancer.
Chimeric antigen receptor therapy
CAR-T in EOC is a potentially novel way to fight 
metastatic ovarian cancer. CAR-T is a complicated 
and expensive process that has shown promise 
in killing cancer cells in a host of disease sites. It 
involves extraction of host T cells and use of gene 
editing to induce these cells to express chimeric 
antibodies on the cell surface, which then go and 
attach to cancer cells in the host when reintroduced. 
This type of therapy has shown promise mainly in 
blood malignancies, but a potentially significant 
application exists in solid tumors such as ovarian 
cancer. This is because ovarian cancer cells over-
express MUC 16, which allows them to escape 
immune surveillance by host defense systems. A 
preliminary paper in Nature BME reported efficacy 
in tumor reduction in mouse models of ovarian 
cancer.132 Although these data are promising, CAR-T 
remains in its infancy for treatment of EOC.
Quality of life and palliative care
Providing comprehensive cancer care is a commitment 
to recognizing that cancer care is a lifelong journey, 
exposing many patients to a multitude of relapses 
and treatment related adverse events that have the 
potential to negatively affect quality of life. The NCCN 
has guidelines to help oncology providers to optimize 
symptom management early in the disease process 
and feel comfortable discussing goals of care so that 
they align with the values, beliefs, and cultures of 
their patients as well as patients’ families and care 
givers.133 The goal of palliative care is to anticipate, 
prevent, and reduce suffering and to support the best 
possible quality of life, regardless of cancer stage or 
need for additional therapies. When integrated early, 
palliative care has been shown to have a profound 
effect on quality of life while reducing symptom 
intensity, particularly among patients with advanced 
cancer.134 Over the past 20 years, palliative care has 
developed into an integral part of comprehensive care, 
with the goal of early intervention to optimize quality 
of life with potential to improve survival outcomes as 
well.135 136 Importantly, this advancement in clinical 
care is equally matched by robust efforts in the 
research arena, as ongoing efforts are being made to 
integrate patient centered outcomes in clinical trial 
designs. Although palliative care should be started 
early in the disease process to optimize quality of 
life, we acknowledge that it becomes the primary 
focus of care when disease directed, life prolonging 
therapies are no longer effective or desired. Shared 
decision making between patients and oncologists 
is critical when selecting next treatment strategies, 
ensuring that these discussions include acceptable 
safety profile, balance symptom benefit with risks, 
and achieve a common goal.
Guidelines
The NCCN guidelines serve as internationally 
accepted standards to help to improve high quality, 
high value cancer care worldwide. The NCCN has 
an active presence in Europe, including more than 
140 000 registered European users and almost 
720 000 NCCN Clinical Practice Guidelines in 
Oncology (NCCN guidelines) downloaded in 2018.137 
The guidelines panel consists of members only from 
the US, but evidence based practices for ovarian 
cancer management stem from large, multicenter 
trials that have been conducted both in the US 
and internationally. Although NCCN guidelines 
are consistent with European Society for Medical 
Oncology guidelines, the section “Principles of 
systemic therapy” reflects specific therapeutic agents 
that are based on US FDA approval. Specific to the 
material covered in this review, we have highlighted 
some differences in indication and approval dates for 
PARP inhibitors.
The Journal of Clinical Oncology recently published 
a special issue devoted to summarizing the most 
important developments in treating gynecologic 
cancers.138 Invited authors included both US and 
internationally renowned oncologists who shared 
evidence based practices that have been widely 
adopted to achieve improved outcomes of women 
with gynecologic malignancies. We used this series 
of articles as a foundation for this review and made 
sure to site all relevant articles on ovarian cancer 
management.
Conclusions
EOC remains the most lethal gynecologic cancer, 
with most women presenting with advanced stage 
disease and five year survival rates approximating 
48%.2 Surgical cytoreduction is a strong predictor 
of prognosis, as a direct correlation exists between 
the extent of postsurgical tumor residuum and 
progression-free and overall survival.38 39 PCS 
followed by platinum based chemotherapy remains 
the standard treatment for patients with advanced 
stage EOC, but neoadjuvant chemotherapy may 
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be considered for patients who are not likely 
to achieve optimal cytoreduction or who are 
poor surgical candidates.30 Research on first 
line treatment has focused on optimization of 
conventional chemotherapy with platinum/taxane 
doublet (for example, dose intensity, dose density, 
and incorporation of different agents, as well as 
intraperitoneal drug administration) and extended 
maintenance with cytotoxic chemotherapy during 
remission. Despite these advances, most patients 
with advanced stage disease experience relapse, and 
the likelihood of responding to subsequent courses 
of platinum based chemotherapy greatly depends 
on the platinum-free interval. Fortunately, advances 
in multiplex panels for cancer susceptibility for 
both germline and somatic mutations have led to 
several management strategies that have changed 
practice: universal genetic screening for all women 
with newly diagnosed EOC; targeted therapies such 
as bevacizumab and/or PARP inhibitors for first 
line maintenance therapy; and PARP inhibitor as 
monotherapy in the recurrent setting. Nevertheless, 
a greater understanding of the molecular landscape 
of EOC is needed to improve survival outcomes, 
especially for rare chemotherapy resistant histo-
logies. Immediate research priorities should be 
aimed at developing robust clinical trials that 
test novel, targeted therapies that are supported 
by predictive biomarkers, integrate evaluation of 
mechanisms of sensitivity and resistance,139 and 
incorporate patient centered outcomes and quality of 
life measures.
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